Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47390
Title: Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
Authors: Gürbüz, Mustafa
Akkuş, Erman
Sakin Abdullah
Urvay, Semiha
Demiray, Atike Gökçen
Şahin, Süleyman
Şakalar, Teoman
Erol, Cihan
Şendur, Mehmet Ali Nahit
Şahin, Ahmet Bilgehan
Çubukçu, Erdem
Güven, Deniz Can
Kılıçkap, Saadettin
Ergün, Yakup
Uncu, Doğan
Turhal, Nazım Serdar
Üskent, Necdet
Çınkır, Havva Yeşil
Demir, Atakan
Acar, Ramazan
Karadurmuş, Nuri
Türker, Sema
Altınbaş, Mustafa
Karaoğlan, Mert
Şenler, Filiz Çay
Keywords: Chemotherapy
Gastric cancer
HER2
Maintenance
Trastuzumab
capecitabine
cisplatin
epidermal growth factor receptor 2
fluorouracil
folinic acid
oxaliplatin
trastuzumab
antineoplastic agent
capecitabine
epidermal growth factor receptor 2
trastuzumab
adjuvant chemoradiotherapy
adult
aged
anemia
Article
bone metastasis
cardiotoxicity
clinical article
colorectal adenocarcinoma
diarrhea
drug efficacy
drug safety
fatigue
febrile neutropenia
female
fever
hand foot syndrome
human
infusion related reaction
liver metastasis
lung metastasis
lymph node metastasis
maintenance therapy
male
multiple cycle treatment
nausea
neoadjuvant chemotherapy
neutropenia
observational study
overall survival
peritoneum metastasis
progression free survival
rash
retrospective study
stomach adenocarcinoma
thrombocytopenia
Turkey (republic)
vomiting
clinical trial
multicenter study
pathology
stomach tumor
Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Humans
Receptor, ErbB-2
Retrospective Studies
Stomach Neoplasms
Trastuzumab
Publisher: Springer
Abstract: Purpose: In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab ± capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods: This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab ± capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results: About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7–51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2–30). The median PFS of the patients was 12.0 months (95% CI 10.3–13.7), and median OS was 17.4 months (95% CI 15.2–19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion: Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
URI: https://doi.org/10.1007/s12029-021-00594-1
https://hdl.handle.net/11499/47390
ISSN: 1941-6628
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu

Show full item record



CORE Recommender

SCOPUSTM   
Citations

4
checked on Oct 13, 2024

Page view(s)

48
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.